Ra Medical Systems Granted U.S. Patent for Laser Ablation Catheters with Expanded Ablation Area
05 Avril 2022 - 2:30PM
Business Wire
Ra Medical Systems, Inc. (NYSE American: RMED), a medical
device company focusing on developing its excimer laser system to
treat vascular diseases, announces the United States Patent and
Trademark Office has granted the company a patent for liquid-filled
laser ablation catheters with expanded distal optical windows. U.S.
patent 11,284,941 (the ’941 patent), titled Laser Ablation
Catheters Having Expanded Distal Tip Windows for Efficient Tissue
Ablation, describes a catheter with an increased ablation surface
area at the distal catheter tip. This is the 11th U.S. patent
issued to Ra Medical and is a natural evolution in the patent
coverage of the company’s DABRA technology.
“The design covered by this patent is important because it
allows us to achieve an increased ablation area without increasing
the overall catheter profile. We believe this will make it easier
for us to develop a family of products to address larger diameter
vessels using the same base platform technology. The patent marks
another milestone in our intellectual property strategy to fortify
our competitive position both now and in the future,” said Will
McGuire, Ra Medical Systems CEO.
About Ra Medical Systems
Ra Medical Systems manufactures the DABRA excimer laser and
catheters for the treatment of certain vascular diseases. DABRA has
been cleared by the FDA for crossing chronic total occlusions in
patients with symptomatic infrainguinal lower extremity vascular
disease and has an intended use for ablating a channel in occlusive
peripheral vascular disease. In addition, DABRA has been granted CE
mark clearance for the endovascular treatment of infrainguinal
arteries via atherectomy and for crossing total occlusions. DABRA
excimer lasers and catheters are manufactured in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is
licensed by the State of California to manufacture sterile,
single-use catheters in clean room environments.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical’s future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “could,” “intends,” “target,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these words or other similar terms or
expressions that concern Ra Medical’s future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
Ra Medical’s business strategy, the potential of the DABRA system
for new applications of use, the market opportunity and growth of
current and potential markets and its ability to continue to manage
expenses and cash burn rate at sustainable levels. Ra Medical’s
expectations and beliefs regarding these matters may not
materialize, and actual results in future periods are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected or implied by such forward-looking
statements. The potential risks and uncertainties which contribute
to the uncertain nature of these statements include, among others,
challenges inherent in developing, manufacturing, launching,
marketing, and selling new products or new applications of use;
risks associated with acceptance of DABRA devices for current and
potential applications of use and procedures performed using such
devices by physicians, payors, and other third parties; development
and acceptance of new products, product enhancements or
applications of use; clinical and statistical verification of the
benefits achieved via the use of Ra Medical’s products; the results
from our clinical trials, which may not support intended
indications or may require Ra Medical to conduct additional
clinical trials or modify ongoing clinical trials; challenges
related to commencement, patient enrollment, completion, an
analysis of clinical trials; Ra Medical’s ability to manage
operating expenses; Ra Medical’s ability to recruit and retain
management and key personnel; Ra Medical’s need to comply with
complex and evolving laws and regulations; intense and increasing
competition and consolidation in Ra Medical’s industry; the impact
of rapid technological change; adverse outcome of regulatory
inspections; impacts from public health crises, such as the
Covid-19 pandemic, geopolitical conflicts, such as Russia’s
invasion of Ukraine and related sanctions against Russia and
Belarus, or natural disasters; and the other risks and
uncertainties described in Ra Medical’s news releases and filings
with the Securities and Exchange Commission. Information on these
and additional risks, uncertainties, and other information
affecting Ra Medical’s business and operating results is contained
in Ra Medical’s Annual Report on Form 10-K for the year ended
December 31, 2021 and in its other filings with the Securities and
Exchange Commission. The forward-looking statements in this press
release are based on information available to Ra Medical as of the
date hereof, and Ra Medical disclaims any obligation to update any
forward-looking statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405005762/en/
Investor Relations Contact: LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
Ra Medical Systems (AMEX:RMED)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Ra Medical Systems (AMEX:RMED)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024